Abstract | PURPOSE: METHODS: A retrospective chart review was performed to identify patients who had demonstrated an allergic reaction to apraclonidine of sufficient severity to result in drug discontinuation. Within this group, those patients subsequently treated with brimonidine were isolated and analyzed, and the incidence of allergy to brimonidine was determined. RESULTS: CONCLUSIONS: In this study, the risk of developing an allergic reaction to brimonidine in patients known to be allergic to apraclonidine is 22.7%. This lack of a strong cross-reactive allergic response possibly suggests different allergic mechanisms for these two medications. Therefore, brimonidine therapy in patients previously identified as being allergic to apraclonidine is safe and does not result in a cross-reactive response in the great majority of patients (or in nearly four of five patients).
|
Authors | G C Williams, S Orengo-Nania, R L Gross |
Journal | Journal of glaucoma
(J Glaucoma)
Vol. 9
Issue 3
Pg. 235-8
(Jun 2000)
ISSN: 1057-0829 [Print] United States |
PMID | 10877374
(Publication Type: Journal Article)
|
Chemical References |
- Adrenergic alpha-Agonists
- Quinoxalines
- Brimonidine Tartrate
- apraclonidine
- Clonidine
|
Topics |
- Adolescent
- Adrenergic alpha-Agonists
(adverse effects)
- Adult
- Aged
- Aged, 80 and over
- Brimonidine Tartrate
- Clonidine
(adverse effects, analogs & derivatives)
- Conjunctivitis
(chemically induced)
- Cross Reactions
- Dermatitis, Allergic Contact
(etiology)
- Drug Hypersensitivity
(etiology)
- Female
- Glaucoma
(drug therapy)
- Humans
- Hyperemia
(chemically induced)
- Incidence
- Male
- Middle Aged
- Quinoxalines
(adverse effects)
- Retrospective Studies
- Risk Factors
|